Last reviewed · How we verify
IOXAGLIC ACID
At a glance
| Generic name | IOXAGLIC ACID |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
Common side effects
Key clinical trials
- Imaging Study of 3D-CBCT Sialography and MRI Sialography in Non Tumor Salivary Diseases
- Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients (IDPC Trial)
- Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography (PHASE4)
- Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration (PHASE3)
- RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |